Erratum : High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group(Journal of Hematology and Oncology (2016) 9 (133) DOI: 10.1186/s13045-015-0215-4);High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group

Journal of Hematology and Oncology

Volumn 8, Issue 1, 2015, Pages 1-1

  Laszlo, George S ^a   Alonzo, Todd A ^b,c   Gudgeon, Chelsea J ^a   Harrington, Kimberly H ^a   Kentsis, Alex ^d,e   Gerbing, Robert B ^c   Wang, Yi Cheng ^c   Ries, Rhonda E ^a   Raimondi, Susana C ^c,f   Hirsch, Betsy A ^c,g   Gamis, Alan S ^c,h   Meshinchi, Soheil ^a,c,i   Walter, Roland B ^a,j  

^a USA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^h CHILDREN S MERCY HOSPITAL   (United States)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

AAML0531; Acute myeloid leukemia (AML); Adverse risk; Biomarker; Children's Oncology Group (COG); Myocyte enhancer factor 2C (MEF2C); Pediatric; Transcription factor

Indexed keywords

BETA GLUCURONIDASE; MESSENGER RNA; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; GEMTUZUMAB; MEF2C PROTEIN, HUMAN; MONOCLONAL ANTIBODY; MYOCYTE ENHANCER FACTOR 2;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; EVENT FREE SURVIVAL; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; INFANT; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MEF2C GENE; NEWBORN; OVERALL SURVIVAL; PREVALENCE; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ACUTE DISEASE; BONE MARROW; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOID; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BONE MARROW; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID; MALE; MEF2 TRANSCRIPTION FACTORS; MULTIVARIATE ANALYSIS; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84944691382     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-016-0364-0     Document Type: Erratum

References (37)

1. Black BL, Olson EN. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol. 1998;14:167-96.
2. Lin Q, Schwarz J, Bucana C, Olson EN. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science. 1997;276(5317):1404-7.
3. Canté-Barrett K, Pieters R, Meijerink JP. Myocyte enhancer factor 2C in hematopoiesis and leukemia. Oncogene. 2014;33(4):403-10.
4. Schüler A, Schwieger M, Engelmann A, Weber K, Horn S, Müller U, et al. The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate. Blood. 2008;111(9):4532-41.
5. Stehling-Sun S, Dade J, Nutt SL, DeKoter RP, Camargo FD. Regulation of lymphoid versus myeloid fate 'choice' by the transcription factor Mef2c. Nat Immunol. 2009;10(3):289-96.
6. Zheng R, Wang X, Studzinski GP. 1,25-Dihydroxyvitamin D3 induces monocytic differentiation of human myeloid leukemia cells by regulating C/EBPbeta expression through MEF2C. J Steroid Biochem Mol Biol. 2015;148:132-7.
7. Nagel S, Meyer C, Quentmeier H, Kaufmann M, Drexler HG, MacLeod RA. MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines. Leukemia. 2008;22(3):600-7.
8. Nagel S, Venturini L, Meyer C, Kaufmann M, Scherr M, Drexler HG, et al. Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2011;52(2):290-7.
9. Homminga I, Pieters R, Langerak AW, de Rooi JJ, Stubbs A, Verstegen M, et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell. 2011;19(4):484-97.
10. Zuurbier L, Gutierrez A, Mullighan CG, Cante-Barrett K, Gevaert AO, de Rooi J, et al. Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors. Haematologica. 2014;99(1):94-102.
11. Schwieger M, Schüler A, Forster M, Engelmann A, Arnold MA, Delwel R, et al. Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C. Blood. 2009;114(12):2476-88.
12. Somervaille TCP, Cleary ML. Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells? Int J Hematol. 2010;91(5):735-41.
13. de Boer J, Walf-Vorderwulbecke V, Williams O. In focus: MLL-rearranged leukemia. Leukemia. 2013;27(6):1224-8.
14. Gole B, Wiesmüller L. Leukemogenic rearrangements at the mixed lineage leukemia gene (MLL)-multiple rather than a single mechanism. Front Cell Dev Biol. 2015;3:41.
15. Yokoyama A. Molecular mechanisms of MLL-associated leukemia. Int J Hematol. 2015;101(4):352-61.
16. Jin G, Yamazaki Y, Takuwa M, Takahara T, Kaneko K, Kuwata T, et al. Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood. 2007;109(9):3998-4005.
17. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, et al. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood. 2011;117(13):3617-28.
18. Glass C, Wilson M, Gonzalez R, Zhang Y, Perkins AS. The role of EVI1 in myeloid malignancies. Blood Cells Mol Dis. 2014;53(1-2):67-76.
19. Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, et al. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood. 2012;119(24):5838-49.
20. Rommer A, Steinmetz B, Herbst F, Hackl H, Heffeter P, Heilos D, et al. EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells. PLoS One. 2013;8(2):e56308.
21. Heller G, Rommer A, Steinleitner K, Etzler J, Hackl H, Heffeter P, et al. EVI1 promotes tumor growth via transcriptional repression of MS4A3. J Hematol Oncol. 2015;8:28.
22. Du Y, Spence SE, Jenkins NA, Copeland NG. Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. Blood. 2005;106(7):2498-505.
23. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442(7104):818-22.
24. Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol. 2014;32(27):3021-32.
25. Vitali C, Bassani C, Chiodoni C, Fellini E, Guarnotta C, Miotti S, et al. SOCS2 controls proliferation and stemness of hematopoietic cells under stress conditions and its deregulation marks unfavorable acute leukemias. Cancer Res. 2015;75(11):2387-99.
26. Laszlo GS, Ries RE, Gudgeon CJ, Harrington KH, Alonzo TA, Gerbing RB, et al. High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2014;55(12):2817-21.
27. Badodi S, Baruffaldi F, Ganassi M, Battini R, Molinari S. Phosphorylationdependent degradation of MEF2C contributes to regulate G2/M transition. Cell Cycle. 2015;14(10):1517-28.
28. Seita J, Sahoo D, Rossi DJ, Bhattacharya D, Serwold T, Inlay MA, et al. Gene Expression Commons: an open platform for absolute gene expression profiling. PLoS One. 2012;7(7):e40321.
29. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA. 2010;304(24):2706-15.
30. Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014;7(1):70.
31. Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2009;113(26):6558-66.
32. Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood. 2012;120(8):1581-8.
33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8.
34. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101-8.
35. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-81.
36. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. Hoboken, NJ: John Wiley & Sons, Inc.; 2002.
37. Cox DR. Regression models and life tables (with discussion). J R Statist Soc. 1972;34(B):187-220.